Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT03447470 Suspended - Cancer Clinical Trials

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Start date: February 5, 2018
Phase: Phase 1
Study type: Interventional

The purpose of Part A of this study is to determine the safety and tolerability of RXC004 in patients with advanced malignancies. In order to define the doses and schedules for further clinical evaluation.

NCT ID: NCT02943733 Suspended - Cancer Clinical Trials

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Start date: August 22, 2017
Phase: Phase 1
Study type: Interventional

The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.

NCT ID: NCT02470715 Suspended - Cancer Clinical Trials

Identifying Molecular Drivers of Cancer

Start date: April 2014
Phase: N/A
Study type: Observational

The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.

NCT ID: NCT02291055 Suspended - Cancer Clinical Trials

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their recurrent/persistent or metastatic cervical cancer.

NCT ID: NCT02069080 Suspended - Cancer Clinical Trials

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

Start date: February 20, 2014
Phase: Early Phase 1
Study type: Interventional

In mouse models and in patients, expression of the chemokine receptor CXCR4 on various cancers has been correlated with aggressive biological behavior, including increased rates and certain sites of metastasis, and decreased survival. Plerixafor (Mozobil ; Genzyme; Cambridge, MA) has been identified as a specific inhibitor of CXCR4, and it is currently approved by the Food and Drug Administration as a stem-cell mobilizing agent in combination with granulocyte colony-stimulating factor in the treatment of non-Hodgkin's lymphoma and multiple myeloma. Our group has recently shown that plerixafor can be labeled with the positron-emitting radionuclide copper-64((64)Cu) to form (64)Cu-plerixafor, which can be used to visualize CXCR4-positive tumor xenografts in mice using small-animal positron emission tomography (PET). Determining CXCR4 expression in tumors using (64)Cu-plerixafor and PET/computerized tomography (CT) scanning could be useful in predicting tumor behavior and responses to current and experimental therapies, including therapies targeting CXCR4, which could lead to more effective personalized cancer treatments. This study s primary objective is to evaluate (64)Cu-plerixafor as an imaging agent for quantifying CXCR4 expression in subjects (greater than or equal to 18 years of age) with cancer; at least 1 detectable solid tumor of greater than or equal to 2 cm in diameter found outside of the lymph nodes, bone marrow, liver, gallbladder, kidney, bladder, and brain; and preexisting biopsies of the tumors obtained since the first detection of the current occurrence/recurrence of disease. The secondary objectives are to correlate (64)Cu-plerixafor standardized uptake value in the target lesion with the level of CXCR4 expression detected via immunohistochemistry and to calculate human dosimetry for (64)Cu-plerixafor. Preexisting tumor biopsies from less than or equal to 75 subjects recruited from the National Cancer Institute and the Georgetown University Hospital will be evaluated for CXCR4 expression via immunohistochemistry. Subjects who meet the eligibility criteria will continue onto the study. Five subjects with CXCR4-positive tumor biopsies will be administered an initial intravenous infusion of (64)Cu-plerixafor (8 +/-0.8 mCi ; 0.48+/- 0.048 rem; not to exceed 5 microg of (64)Cu -plerixafor) over 2 minutes. They will then undergo an initial low-dose transmission CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ. The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor biopsies will be administered 64Cu-plerixafor at the same, or a newly calculated dose, and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion, depending on the dosimetry results. All subjects will undergo one comprehensive final study visit between study days 19 and 23 (11-17 days after injection with (64)Cu -plerixafor). Additionally, blood will be collected 2 more times between study days 13-16 and study days 26-30 to measure blood cell counts.

NCT ID: NCT01604863 Suspended - Cancer Clinical Trials

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.

NCT ID: NCT01189409 Suspended - Cancer Clinical Trials

Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients

Start date: June 2010
Phase: Phase 4
Study type: Interventional

This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and Symptom Management/Palliative Care clinics. Each participating patient will be randomly assigned to one of two treatment groups.

NCT ID: NCT01050725 Suspended - Cancer Clinical Trials

Pilot Study of Biomarkers for Radiation Therapy

Start date: November 2009
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether specific assays of DNA damage repair proteins can be used in patients undergoing radiation therapy. The ultimate goal of this research is to develop clinically useful biomarkers from blood samples that could be used to customize radiation treatment for individuals, leading to reduced side effects and improved outcomes.

NCT ID: NCT00523094 Suspended - Cancer Clinical Trials

Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure

Start date: September 2007
Phase: N/A
Study type: Observational

The primary objective of this study is to estimate the accuracy of the pre-operative VRI quantitative results versus the gold standard pre-operative perfusion scan. The secondary objective is to assess the correlation of the predicted post-operative lung function with the observed post-operative lung function (forced expiratory volume in 1 second [FEV1] and diffusing capacity of the lung for carbon monoxide [DLCO]) in patients who underwent surgical resection.

NCT ID: NCT00499499 Suspended - Cancer Clinical Trials

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate E7107 in patients with solid tumors. This is an open label, dose-escalation study of E7107. The maximum tolerated dose (MTD) of the single agent will be established by determining the occurrence of dose limiting toxicities during the first three weeks of therapy (Cycle 1). Patients in this study will be treated at multiple dose levels, starting at 0.6 mg/m^2. Patients will receive E7107 as a 30-minute intravenous infusion on Days 1 and 8 every 21 Days.